艾司氯胺酮鼻喷剂联合口服抗抑郁药预防难治性抑郁复发
这项3期随机撤药试验纳入705例难治性抑郁症成人,经艾司氯胺酮鼻喷剂联合口服抗抑郁药治疗16周后,297例进入随机维持阶段。
要点
- 稳定缓解者继续艾司氯胺酮联合口服药可降低51%复发风险(HR 0.49,95%CI 0.29-0.84)。
- 稳定应答者继续艾司氯胺酮联合口服药可降低70%复发风险(HR 0.30,95%CI 0.16-0.55)。
- 常见不良事件为短暂味觉障碍、眩晕、解离、嗜睡和头晕(发生率20.4%-27.0%)。
核心结论
- 对艾司氯胺酮治疗后达到缓解或应答的难治性抑郁症患者,继续艾司氯胺酮鼻喷剂联合口服抗抑郁药在延迟复发方面优于口服抗抑郁药联合安慰剂鼻喷剂。
研究设计与样本
- 455例进入优化阶段接受艾司氯胺酮鼻喷剂(56或84 mg)联合口服抗抑郁药治疗16周,其中297例达到稳定缓解或稳定应答后进入随机撤药阶段。
- 稳定缓解者和稳定应答者(未缓解)按1:1随机继续艾司氯胺酮鼻喷剂或换用安慰剂鼻喷剂,两组均继续口服抗抑郁药。
主要发现
- 随机维持阶段297例成人平均年龄46.3岁(SD 11.13),女性197例(66.3%)。
- 稳定缓解者中艾司氯胺酮联合抗抑郁药降低复发风险51%(HR 0.49;95%CI 0.29-0.84),稳定应答者中降低70%(HR 0.30;95%CI 0.16-0.55)。
- 随机分组后艾司氯胺酮治疗患者最常见不良事件为短暂味觉障碍、眩晕、解离、嗜睡和头晕(发生率20.4%-27.0%),在抗抑郁药联合安慰剂组中每种报告均少于7%。
临床怎么用
- 对艾司氯胺酮鼻喷剂联合口服抗抑郁药诱导治疗16周后达到稳定缓解或稳定应答的难治性抑郁症患者,可考虑继续艾司氯胺酮鼻喷剂联合口服抗抑郁药维持治疗以延迟复发。
- 维持治疗期间需监测短暂味觉障碍、眩晕、解离、嗜睡和头晕等不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Controlled studies have shown short-term efficacy of esketamine for treatment-resistant depression (TRD), but long-term effects remain to be established. OBJECTIVE: To assess the efficacy of esketamine nasal spray plus an oral antidepressant compared with an oral antidepressant plus placebo nasal spray in delaying relapse of depressive symptoms in patients with TRD in stable remission after an induction and optimization course of esketamine nasal spray plus an oral antidepressant. DESIGN, SETTING, AND PARTICIPANTS: In this phase 3, multicenter, double-blind, randomized withdrawal study conducted from October 6, 2015, to February 15, 2018, at outpatient referral centers, 705 adults with prospectively confirmed TRD were enrolled; 455 entered the optimization phase and were treated with esketamine nasal spray (56 or 84 mg) plus an oral antidepressant. After 16 weeks of esketamine treatment, 297 who achieved stable remission or stable response entered the randomized withdrawal phase. INTERVENTIONS: Patients who achieved stable remission and those who achieved stable response (without remission) were randomized 1:1 to continue esketamine nasal spray or discontinue esketamine treatment and switch to placebo nasal spray, with oral antidepressant treatment continued in each group. MAIN OUTCOMES AND MEASURES: Time to relapse was examined in patients who achieved stable remission, as assessed using a weighted combination log-rank test. RESULTS: Among the 297 adults (mean age [SD], 46.3 [11.13] years; 197 [66.3%] female) who entered the randomized maintenance phase, 176 achieved stable remission; 24 (26.7%) in the esketamine and antidepressant group and 39 (45.3%) in the antidepressant and placebo group experienced relapse (log-rank P = .003, number needed to treat [NNT], 6). Among the 121 who achieved stable response, 16 (25.8%) in the esketamine and antidepressant group and 34 (57.6%) in the antidepressant and placebo group experienced relapse (log-rank P < .001, NNT, 4). Esketamine and antidepressant treatment decreased the risk of relapse by 51% (hazard ratio [HR], 0.49; 95% CI, 0.29-0.84) among patients who achieved stable remission and 70% (HR, 0.30; 95% CI, 0.16-0.55) among those who achieved stable response compared with antidepressant and placebo treatment. The most common adverse events reported for esketamine-treated patients after randomization were transient dysgeusia, vertigo, dissociation, somnolence, and dizziness (incidence, 20.4%-27.0%), each reported in fewer patients (<7%) treated with an antidepressant and placebo. CONCLUSIONS AND RELEVANCE: For patients with TRD who experienced remission or response after esketamine treatment, continuation of esketamine nasal spray in addition to oral antidepressant treatment resulted in clinically meaningful superiority in delaying relapse compared with antidepressant plus placebo. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02493868.
引用
- Daly EJ, Trivedi MH, Janik A, et al. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2019. PMID: 31166571. doi:10.1001/jamapsychiatry.2019.1189
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。